Accelerated Tooth Movement With AcceleDent® and Aligners - a Pilot Project
Launched by UNIVERSITY OF WASHINGTON · May 4, 2015
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
This study will be a parallel group, triple-blind randomized clinical trial comparing two groups of subjects with 12 participants in each group. Subjects will be randomized to receive one of two vibrational units, which will differ in frequency and/or amplitude of vibration. The subjects will be asked to change their aligners every week instead of every 2 weeks, which is common with Invisalign.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with malocclusions that require minor or no anterior-posterior or transverse correction in the posterior teeth, and are planned for \<= 25 aligners to complete treatment.
- • 2. Treatment must be dual arch in order for patients to qualify for this study.
- • 3. Patients must be 18 years or older
- Exclusion Criteria:
- • 1. Patients with systematic diseases or syndromes
- • 2. Patients with a history or current use of Bisphosphonates
- • 3. Patients with current use of nonsteroidal anti-inflammatory drugs (NSAIDs)prostaglandin inhibitors.
- • 4. Patients with generalized moderate to severe periodontitis
- • 5. Patients with active oral hard tissue or soft tissue lesions
- • 6. Patients with chronic oral and maxillofacial conditions such as trigeminal neuralgia, temporomandibular disorder and orofacial pain.
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Richmond, British Columbia, Canada
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Greg Huang
Principal Investigator
UW
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials